A distinct population of Low-Density Granulocytes with unique features associated with subclinical vascular alterations in Systemic Lupus Erythematosus - Report - MDSpire
Advertisement
A distinct population of Low-Density Granulocytes with unique features associated with subclinical vascular alterations in Systemic Lupus Erythematosus
Clinical Report: Unique Low-Density Granulocytes in Systemic Lupus Erythematosus
Overview
This study identifies a novel subset of low-density granulocytes (LDGs) in systemic lupus erythematosus (SLE) patients, linked to subclinical vascular changes. The findings suggest that these cells may play a significant role in immune dysregulation and cardiovascular complications in SLE.
Background
Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder that can lead to significant morbidity, particularly due to cardiovascular complications. Low-density granulocytes (LDGs) have been implicated in the pathogenesis of SLE, and their role in vascular inflammation is of growing interest. Understanding the unique subsets of myeloid cells in SLE may provide insights into disease mechanisms and potential therapeutic targets.
Data Highlights
Parameter
Value
Patients with SLE
143
Non-disease controls
42
Non-autoimmune atherosclerotic individuals
22
Correlation with Th1 cells
ρ=0.230; p=0.006
Correlation with Th17 cells
ρ=0.244; p=0.004
Correlation with Treg cells
ρ=-0.219; p=0.010
Key Findings
A distinct CD14⁺CD15⁺CD16⁺ myeloid population was identified in SLE patients.
This population, termed APC-like neutrophils (nAPC-like), displayed unique phenotypic characteristics.
nAPC-like cells correlated significantly with SLEDAI and anti-dsDNA titers.
Increased levels of nAPC-like were observed in patients with traditional cardiovascular risk factors.
A minor CD16dim_nAPC-like subset was expanded in SLE and correlated with serum IL-6 and BLyS.
Clinical Implications
The identification of nAPC-like neutrophils in SLE patients highlights the need for further investigation into their role in immune dysregulation and cardiovascular risk. Clinicians should consider monitoring these cell populations as potential biomarkers for vascular complications in SLE.
Conclusion
This study uncovers a previously unrecognized subset of LDGs that may contribute to vascular changes in SLE, emphasizing the importance of understanding myeloid cell dynamics in autoimmune diseases.
